Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 5/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358828 | 1.00 | CA1 (0.39) | CA1CA2USP30NPC1L1AURKA | |
| SCHEMBL1359821 | 1.00 | CA1 (0.39) | CA1CA2USP30NPC1L1AURKA | |
| SCHEMBL1360761 | 0.91 | PARP1 (0.40) | NPC1L1PARP1BRD4HDAC3HDAC1 | |
| SCHEMBL1359038 | 0.88 | NPC1L1 (0.39) | NPC1L1GAA | |
| SCHEMBL1358334 | 0.87 | CYP3A4 (0.37) | USP30BRD4GAA | |
| SCHEMBL1358332 | 0.87 | CYP3A4 (0.37) | USP30BRD4GAA | |
| SCHEMBL1359797 | 0.85 | CHEK1 (0.38) | NPC1L1ALOX5APFEN1GAA | |
| SCHEMBL1357835 | 0.85 | ACACB (0.37) | NPC1L1 | |
| SCHEMBL1359812 | 0.85 | KDM1A (0.39) | PADI4GAA | |
| SCHEMBL1357912 | 0.85 | KDM1A (0.39) | PADI4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | claimed |
| EP-2334662-A1 | PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | claimed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | claimed |
| WO-2010034671-A1 | PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | CA1 4762/4885CA2 4351/4885USP30 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.